Blood cancers

Cheap and rapid ‘non-viral’ CAR T-cell therapy in Monash sights

Monash University researchers are aiming to overcome the high costs and lengthy manufacturing times associated with CAR-T cell therapy by eliminating the use of an inactive virus vector to genetically encode the T cells. Using powerful nanoscale tools, scientists at the Monash Institute of Pharmaceutical Sciences (MIPS) believe they can overcome the most expensive and ...

Already a member?

Login to keep reading.

© 2020 the limbic